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Introduction. Liver biopsy is an invasive determinator for hepatic ﬁbrosis. Serum biomarkers can probably be used as an alternative
to liver biopsy in assessment of the degree of ﬁbrosis in patients with chronic Hepatitis C. Method. Eighty patients with chronic
Hepatitis C were included in the study using simple nonrandom sampeling metod. After fulﬁllment of liver biopsy, the patients
were categorized according to the METAVIR Scoring system. The Hepascore algorithm is computed based on age, sex, and the
serum levels of total bilirubin, δ-glutamyl transferase, α2-Macroglobulin, and hyaluronic acid. The spearman and ROC tests were
used. Results. According to the liver biopsy results, 12, 25, 20, 7 and 16 patients had F0, F1, F2, F3, and F4, respectively. With
regard to the 0.34 cut-oﬀ point Hepascore had 67%, 56%, 64%, and 56% sensitivity, speciﬁcity, respectively, positive prediction
value (PPV), and negative prediction value (NPV), respectively, for diagnosis of signiﬁcant ﬁbrosis. For a Hepascore cut-oﬀ point
0.61, sensitivity, speciﬁcity, respectively, PPV and NPB 82%, 86%, 70%, and 92% in diagnosis of severe ﬁbrosis. For a Hepascore
cut-oﬀ point 0.84, sensitivity, speciﬁcity, PPV and NPB were respectively 100%, 97%, 89%, and 100% for diagnosis of cirrhosis.
Conclusion. Hepascore has a high value in diagnosis of the level of ﬁbrosis, particularly cirrhosis. Therefore, it can be used for
primary screening of patients to determine the need for liver biopsy.
1.Introduction
The prevalence of hepatitis C virus (HCV) has been esti-
mated to be 3% throughout the world. The severity of the
disease is dependent on the extension of hepatic ﬁbrosis.
Liver biopsy is currently considered as the gold standard
for determination of the grade of ﬁbrosis [1]. Presence
of signiﬁcant ﬁbrosis (F2–4) is accepted as the treatment
indication [2, 3]. Liver biopsy is unfortunately associated
with many complications for patients, including pain, bleed-
ing, and rarely death, high costs, variations in diagnosis of
histological grades, and sampling errors [4]. Furthermore,
liver biopsy can provide only a view of a static or dynamic
disease, and multiple biopsies are required to determine the
disease progression or recurrence of ﬁbrosis. This reveals
the need for noninvasive, precise, and valid methods [5].
Considerable advances have occurred in identiﬁcation of
nonspeciﬁc ﬁbrosis biomarkers. The nonspeciﬁc markers
include age, gender, and laboratory markers of liver damage
or dysfunction (AST, ALT, γ-glutamyl transferase (GGT),
bilirubin, hapatoglobin, platelet count, and prothrombin
time), while metabolic markers are cholesterol, apoprotein
A1 (Apo A1), and α2-macroglobulin (A2M).
So far, the index of ratio of AST to platelet count (APRI)
has been the simplest test using nonspeciﬁc markers, which
is valuable in predicting ﬁbrosis [6–9].
The ﬁbrometer test, which includes hyaluronic acid
(HA), PT test, platelet count, AST, A2M, urea, and age, is
to some extent eﬃcient. Another achievement was the use of
speciﬁc ﬁbrosis biomarkers such as HA, matrix metallopro-
teinase 2, tissue inhibitor of matrix metalloproteinase 1, and
amino-terminalpeptideoftypeIIIprocollagen[1,10].When
used in combination with each other, it is known that these
markers are valid in determining the liver ﬁbrosis score [11].2 Hepatitis Research and Treatment
Table 1: Range of variation for independent variables.
Variable
Marker
HA
(X± std error mean)
GGT
(X± std error mean)
Bilirubin
(X± std error mean)
α = M
(X± std error mean)
Age group∗
18–20yr 34.7 ±5.36 0 ±10.93 2 .9 ±4.92 .1 ±0.15
27–31yr 23.6 ±2.84 3 ±41 5 .3 ±0.67 1.4 ±0.12
32–46yr 21.8 ±4.65 1 .6 ±6.21 5 ±1.31 .9 ±0.2
47–65yr 96.1 ±31.35 9 .3 ±71 6 .5 ±1.53 .4 ±0.2
P value for age∗∗ 0.003
∗∗ 0.42 <0.001∗∗ <0.001∗∗
Sex∗∗∗ Male 29 ±3.34 56 ±4.61 8 .5 ±12 .1 ±0.12
Female 125.95 ±46.33 41.6 ±4.23 2 .2 ±9.63 ±0.37
P value for sex∗∗ <0.001∗∗ 0.19 0.004
∗ 0.004
∗
Biopsy∗
F0 31.5 ± 74 4 .9 ±7.13 1 .5 ±8.91 .7 ±0.1
F1 16.25 ±2.23 9 .25 ±5.41 8 .8 ±1.11 .8 ±0.19
F2 26.16 ±4.56 8 .24 ±8.81 3 .27 ±0.93 2 ±0.24
F3 30.6 ±4.83 2 .33 ±3.11 1 .9 ±1.62 .5 ±0.52
F4 121.97 ±34.57 2 .62 ±10.22 7 ±1.73 .4 ±0.14
P value for biopsy∗∗ <0.001∗∗ 0.003
∗∗ 0.002
∗∗ <0.001∗∗
∗Performed by one-way ANOVA.
∗∗Signiﬁcant at 0.05.
∗∗∗Performed by independent t-test.
Table 2: Frequency distribution for ﬁbrosis severity according to
the biopsy results.
Severity of ﬁbrosis No. of patients %
F0 12 15
F1 25 31.25
F2 20 25
F3 7 8.75
F4 16 20
R e c e n t l y ,s o m ea t t e m p t sh a v eb e e np e r f o r m e dt oi m p r o v e
the nonspeciﬁc indices by use of ﬁbrosis-speciﬁc markers.
Adams et al. suggested Hepascore, which is a combination
of HA, total bilirubin, GGT, A2M, age, and gender [12].
Hepascore was shown to be valid in the HCV population
in Australia and then in two other groups in a European
country (France) [12–14]. The aim of the current study is to
compare the results of liver biopsy of patients with hepatitis
C, genotype 1, in Isfahan with their Hepascore, and also to
determine sensitivity, speciﬁcity, and positive and negative
predictive values of Hepascore.
2.MaterialsandMethods
The participants were in the age range of 18–65, with the
mean age of 35.3 ± 12.7. Out of the participants, 68 patients
(85%) were males.
Among the patients with hepatitis C, genotype 1, who
referred to the GI clinic or ward of Alzahra Hospital from
April to October 2010 and met the inclusion criteria of
the study, 80 patients were included in the study using
nonrandom simple method. The inclusion criteria were the
newly diagnosed patients of hepatitis C, genotype 1, who
were candidates of liver biopsy. If the patients were not
willing to participate in the study, they were excluded.
2.1. Liver Biopsy. All liver biopsies were taken under super-
vision of a hepatology subspecialist using an 18-gauge
Menghini needle or a 16-gauge Trucut needle, with the size
of ≥10mm. The specimens were then evaluated by a single
skilled pathologist for the degree of ﬁbrosis according to the
METAVIRE classiﬁcation [1].
The degree of ﬁbrosis was classiﬁed in a 0–4 scale as
follows: F0: no ﬁbrosis, F1: portal ﬁbrosis alone, F2: portal
ﬁbrosis withrare septae, F3: portal ﬁbrosiswithmany septae,
and F4: cirrhosis. Grades F2, F3, and F4 indicate signiﬁcant
ﬁbrosis, F3 and F4 show severe ﬁbrosis, and F4 indicates
cirrhosis.
2.2. Blood Samples. From all the participants, a 10mL blood
sample was obtained, and its serum was kept at −70◦C.
Determination of serum level of hyaluronic acid (Corgenix,
USA), GGT (Biosystems, Spain), and A2M (Immundiagnos-
tik, German) was performed using enzyme-linked protein
binding assay, and the level of total bilirubin was determined
using Biosystem A15 Autoanalyzer with speciﬁc reagents.
2.3.CalculationofHepascore. TocalculatetheHepascore,the
values obtained for the four biomarkers, A2M, GGT, total
bilirubin, and HA, and the age and gender of the patient are
set in the following formula, which was ﬁrst issued by Adam
et al. [12] in 2005:
Y = EXP

−4.185818 −

0.0249 ∗ age

+(0.7464 ∗ sex)+(1.0039 ∗ A2M)
+(0.0302 ∗ HA)+(0.0691 ∗ Bil-t)
−(0.0012 ∗ GGT)),
Hepascore =
Y
(1+Y)
.
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Figure 1: (a) Relationship between mean of Hepascore and severity of liver ﬁbrosis. (b) Relationship between median of Hepascore and
severity of liver ﬁbrosis.
The value for sex in the above formula is 1 for men and 0 for
women.
2.4. Statistical Analysis. All data was analyzed in the SPSS
software, using rho Spearman and ROC analysis. The P val-
ues below 0.05 were considered to be statistically signiﬁcant.
3. Results
The range of variation, mean, and standard deviation values
for HA, A2M, GGT, and bilirubin is provided in Table 1.
3.1. Liver Histology. The results of liver biopsy for the
patientswereasfollows:12patientswereF0,25werepatients
F1, 20 were patients F2, seven patients were F3, and 16
patients were F4. The frequency distribution for ﬁbrosis
severity according to the biopsy results is demonstrated in
Table 2.
3.2.HepascoreofPatients. Meanandmedian of Hepascorein
diﬀerent degrees of ﬁbrosis (according to biopsy) are shown
in Figures 1(a) and 1(b),r e s p e c t i v e l y .
Correlation between Hepascore and Biopsy Results. According
to the results obtained from Spearman’s correlation test,
there is a relatively strong correlation between severity of
ﬁbrosis estimated by Hepascore and that determined by liver
biopsy (r = 0.465, P = 0.003).4 Hepatitis Research and Treatment
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Figure 2: ROC curve of predictive value in signiﬁcant liver ﬁbrosis.
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Figure 3: ROC curve of predictive value in diagnosis of severe
ﬁbrosis.
3.3.Sensitivity,Speciﬁcity,andPositiveandNegativePredictive
Values of Hepascore. Sensitivity and speciﬁcity of Hepascore
in diagnosis of signiﬁcant ﬁbrosis (F2, F3, and F4 from F0
and F1) in diﬀerent cut-oﬀ points are shown in Figure 2.I n
cut-oﬀ point 0.34, sensitivity, speciﬁcity, PPV, and NPV were
67%, 56%, 64%, and 56%, respectively.
Sensitivity and speciﬁcity of Hepascore in diagnosis of
severe ﬁbrosis (F3 and F4 from F0, F1, and F2) in diﬀerent
cut-oﬀ points are demonstrated in Figure 3. In point 0.61,
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Figure 4: ROC curve of predictive value in diagnosis of cirrhosis.
sensitivity, speciﬁcity, PPV, and NPV were 82%, 86%, 70%,
and 92%, respectively.
Sensitivity and speciﬁcity of Hepascore in diagnosis of
cirrhosis (F4 from F0, F1, F2, and F3) in diﬀerent cut-
oﬀ points are shown in Figure 4. In point 0.84, sensitivity,
speciﬁcity, PPV, and NPV were 100%, 97%, 89%, and 100%,
respectively.
4. Discussion
Prognosis of chronic liver diseases is strongly correlated
with the degree of liver ﬁbrosis. In chronic hepatitis C,
besides having prognostic value, liver ﬁbrosis is related to the
therapeutic approach [15]. So far, no FDA-approved nonin-
vasive method has been proposed for determination of liver
ﬁbrosis. A suggested and growing method is determination
of Hepascore of the patients on the basis of blood markers
of ﬁbrosis. The current study demonstrated that Hepascore
index has a reasonable sensitivity, speciﬁcity, NPV, and PPV.
According to the results obtained, from among the cut-oﬀ
points between 0 and 1, the most appropriate point for
diagnosis of signiﬁcant ﬁbrosis from mild ﬁbrosis and no
ﬁbrosis (F0 and F1) was 0.34. In other studies, cut-oﬀ points
from 0.32 to 0.55 were obtained [1, 12, 14–16].
TheauthorswhodevisedHepascore[10]andalsoAdams
et al. [12] methods suggested cut-oﬀ point 0.5. Becker et
al. suggested point 0.55 as the most appropriate cut-oﬀ
point [1], while Leroy et al. obtained cut-oﬀ point 0.32 [16]
(Table 3).
Considering the above-mentioned points, the sensitivity
of Hepascore in diagnosis of signiﬁcant ﬁbrosis was obtained
to be point 67%. The value was reported to be from 54%
to 82% [1, 12, 14]. Moreover, the speciﬁcity of the method
was determined to be 56%, which was reported to be fromHepatitis Research and Treatment 5
Table 3: Comparison of cut-oﬀ points, sensitivity, speciﬁcity, PPV, and NPV in diﬀerent studies.
Adams et al. [12]L e r o y e t a l . [ 16]H a l f o n e t a l . [ 17]B e c k e r e t a l . [ 1]G u e c h o t e t a l . [ 14] This study
Patients number 104 180 356 391 512 80
F0/F1/F2/F3/F4 (%) 16/27/34/7/16 8/41/22/14/14 4/55/26/11/4 16/34/15/16/19 7/45/18/15/15 15/31/25/8/20
For signiﬁcant ﬁbrosis
Cut-oﬀ 0.5 0.5 0.32 0.55 0.5 0.34
Sensitivity 63% 54% 77% 82% 77% 67%
Speciﬁcity 89% 84% 63% 65% 70% 56%
Positive predictive value / 78% 59% 70% 71% 64%
Negative predictive value / 64% 80% 78% 77% 56%
For sever ﬁbrosis
Cut-oﬀ / 0.84 0.53 0.8 0.6 0.61
Sensitivity / 47% 78% / 80% 82%
Speciﬁcity / 90% 72% 77% 70% 86%
Positive predictive value / 65% 32% 62% 54% 70%
Negative predictive value / 81% 95% / 89% 92%
For cirrhosis
Cut-oﬀ 0.84 / 0.61 / 0.75 0.84
Sensitivity 71% / 92% / 86% 100
Speciﬁcity 89% / 72% / 74% 97%
Positive predictive value / / 11% / 37% 89%
Negative predictive value / 100% / 97% 100
63% to 89% in previously performed studies [1, 10, 12, 16,
17]. The PPV and NPV of the test in diagnosis of signiﬁcant
ﬁbrosis were determined to be 64% and 56%, respectively. In
previous studies, the values were determined to be 59% to
89% and 64% to 80%, respectively [1, 14].
According to the results obtained, the most appropriate
point for diagnosis of severe ﬁbrosis from milder forms of
ﬁbrosis was determined to be 0.61, and the sensitivity and
speciﬁcity were 82% and 86%, respectively. The appropriate
cut-oﬀ points for this purpose were determined to be from
0.53 to 0.84 in previous studies.
We obtained the most appropriate cut-oﬀ point for
diagnosis of cirrhosis for milder forms of ﬁbrosis to be
0.84. At this cut-oﬀ point, sensitivity, speciﬁcity, PPV, and
NPV were determined to be 100%, 97%, 89%, and 100%,
respectively. Adams et al. [12] determined sensitivity and
speciﬁcity of Hepascore in diagnosis of cirrhosis to be 71%
and 84%, respectively. Gu´ echot et al. reported the sensitivity,
speciﬁcity, PPV, and NPV of the test in diagnosis of cirrhosis
to be 86%, 74%, 37%, and 97%, respectively. In spite
of the diﬀerences among the values obtained in diﬀerent
studies, the high sensitivity and NPV were noteworthy in
all the studies. The values obtained for these items were
100% in the current study. Therefore, using Hepascore, one
can surely make decision on performance of screening for
hepatocellular carcinoma, as well as carrying out endoscopy
for evaluation of esophageal varicosis, both of which are
currently rather high-cost and invasive procedures.
Af a c t o rt h a ta ﬀects the above-mentioned elements is the
diﬀerence in frequency distribution of severity of ﬁbrosis in
diﬀerent studies. For instance, the prevalence of signiﬁcant
ﬁbrosis in the current study was 53.8%, while the rate was
reported to be 44% to 51% in other studies. Another cause
forthediﬀerencesistheerrorsinpathologicalinterpretations
and laboratory error. Nevertheless, since in clinical settings
the aim of evaluation of these patients is detection of
signiﬁcantﬁbrosistoinitiate thetreatment,highersensitivity
of the test is of great importance.
As can be observed in Table 3, the ﬁndings of the current
study are to a great extent consistent with other studies with
regard to the relative weakness of Hepascore in diagnosis of
lowerstagesofﬁbrosisanditshighpowerindiagnosisofhigh
stages of ﬁbrosis. However, compared with previously per-
formed studies, the cut-oﬀ point determined in the current
study has a higher sensitivity and speciﬁcity for diagnosis of
severe ﬁbrosis and cirrhosis.
5. Conclusion
Hepascore is highly valuable in diagnosis of the severity of
liver ﬁbrosis and particularly cirrhosis (F4) and can be used
as a primary screening method for diagnosis of the need for
carrying out liver biopsy, which is a method with high costs
and complications.
One of the limitations of the study was its small sample
size, which was due to the economic constraints. With6 Hepatitis Research and Treatment
respect to the promising results obtained, similar study on
a larger population can be performed.
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